Monitor the company's research and development progress in filamin A-targeted therapies, particularly for TSC-related epilepsy. The rebranding signals a strategic refocusing that could influence investor perception and partnership opportunities in the CNS disorder space.
Price Chart
Executive Summary
Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) announced a corporate rebranding to reflect its strategic focus on developing therapies targeting the filamin A protein for central nervous system disorders like TSC-related epilepsy. The company changed its legal name effective March 10, 2026, and its stock ticker symbol will change from SAVA to FLNA effective March 11, 2026. The filing includes amendments to the company's bylaws and restated certificate of incorporation to reflect these changes.
Key Facts
- Cassava Sciences, Inc. changed its name to Filana Therapeutics, Inc. effective March 10, 2026
- The company's stock will trade under the new ticker symbol FLNA effective March 11, 2026
- The rebranding reflects the company's strategic focus on developing therapies targeting the filamin A protein
- The company's primary focus is on treating Tuberous Sclerosis Complex (TSC)-related epilepsy
- TSC-related epilepsy affects approximately 45,000 people in the U.S., with over 60% of patients remaining refractory to current antiepileptic therapies
- The company updated its corporate website to www.filanatx.com
Financial Impact
No direct financial impact disclosed; this is a rebranding exercise
Risk Factors
- The company's investigational product candidates have not been approved for any medical indication
- Clinical results from earlier studies may not be indicative of future results from later-stage trials
- The company operates in the high-risk field of new drug discovery and development
- No assurance that the rebranding will lead to improved market perception or financial performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-007422 |
| Exhibit: ex_930540.htm | 0001437749-26-007422 |
| Exhibit: ex_929959.htm | 0001437749-26-007422 |
| Document: sava20260307_8k.htm | 0001437749-26-007422 |
| Document: 0001437749-26-007422-index-headers.html | 0001437749-26-007422 |
| Document: 0001437749-26-007422-index.html | 0001437749-26-007422 |
| Document: 0001437749-26-007422.txt | 0001437749-26-007422 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $0.6885 | awaiting T+20 | — | $0.6483 (−5.84%) |
Sep 22, 2026 5w ago | 8-K | $1.03 $0.6900 | ▼ −33.01% | ▼ −32.45% | $0.6483 (−37.06%) |
Sep 18, 2026 5w ago | 8-K | $0.7395 $0.6820 | ▲ +7.78% | ▲ +6.87% | $0.6483 (+12.33%) |
Jul 29, 2026 12w ago | 8-K | $0.8696 $0.9244 | ▲ +6.30% | ▲ +1.28% | $0.6483 (−25.45%) |
Jun 15, 2026 19w ago | 8-K | $1.21 $1.15 | ▼ −4.96% | ▼ −4.21% | $0.6483 (−46.42%) |
May 7, 2026 24w ago | 8-K | $1.36 $1.36 | · 0.00% | ▲ +3.14% | $0.6483 (+52.33%) |
May 7, 2026 24w ago | Press Release | $1.36 $1.36 | · 0.00% | ▼ −3.14% | $0.6483 (−52.33%) |
Mar 12, 2026 32w ago | Press Release | $1.95 $1.64 | ▲ +15.90% | ▲ +17.87% | $0.6483 (+66.75%) |
Mar 10, 2026 33w ago | 8-K | $2.38 $1.70 | ▼ −28.57% | ▼ −28.42% | $0.6483 (−72.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers